Phase I Trial of CPI-0209 in Combination With Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Carboplatin (Primary) ; Tulmimetostat (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
Most Recent Events
- 18 Apr 2025 Planned End Date changed from 31 Aug 2028 to 31 Dec 2028.
- 18 Apr 2025 Planned primary completion date changed from 31 May 2027 to 31 Jul 2026.
- 11 Feb 2025 Planned End Date changed from 31 Aug 2029 to 31 Aug 2028.